OCT 06, 2016 09:00 AM PDT

Keynote Speaker - PD-1 cancer immunotherapy

C.E. CREDITS: P.A.C.E. CE | Florida CE
Speakers
  • Professor of Medicine, Harvard Medical School
    Biography
      Gordon J. Freeman, PhD works in the Department of Medical Oncology at Dana-Farber Cancer Institute and is Professor of Medicine at Harvard Medical School. Dr. Freeman earned his BA in Biochemistry and Molecular Biology, and PhD in Microbiology and Molecular Genetics from Harvard University. His research has identified the major pathways that control the immune response by inhibiting T cell activation (PD-1/PD-L1 and B7-2/CTLA-4) or stimulating T cell activation (B7-2/CD28). In 2000, Dr. Freeman discovered PD-L1 and PD-L2, and showed they were ligands for PD-1, thus defining the PD-1 pathway and the drug target: block the interaction. He showed the function of PD-1 was to inhibit immune responses and that blockade enhanced immune responses. He showed that PD-L1 is highly expressed on many solid tumors such as breast and lung, as well as some hematologic malignancies and allows these tumors to inhibit immune attack. He received the 2014 William B. Coley Award for Distinguished Research in Tumor Immunology for this work that led to development of PD-1 pathway blockade for cancer immunotherapy.

    Abstract:

    The immune system is capable of recognizing tumors and eliminates many early malignant cells. However, tumors evolve to evade immune attack, and the tumor microenvironment is immunosuppressive. Engagement of PD-1 by PD-L1 or PD-L2 results in attenuated TCR signaling and inhibition of T-cell immune functions.  Tumors exploit these immune checkpoint pathways to evade immune eradication. Blockade of the PD-1, PD-L1, and CTLA-4 checkpoints is proving to be an effective and durable cancer immunotherapy in a subset of patients in a broad variety of tumor types by allowing the patient to produce an effective anti-tumor immune response. Expression of PD-L1 by tumor cells or infiltrating immune cells correlates with responsiveness to PD-1 or PD-L1 blockade but is an imperfect biomarker since some patients who do not express PD-L1 still respond. A broad range of other immune modulatory targets has been identified and are potential targets for synergizing with immune checkpoint blockade. Advances in understanding T cell coinhibitory pathways have stimulated a new era of immunotherapy with effective drugs to treat cancer.
     


    Show Resources
    You May Also Like
    SEP 05, 2019 04:00 PM CEST
    C.E. CREDITS
    SEP 05, 2019 04:00 PM CEST
    DATE: September 5, 2019TIME: 7:00am PT, 10:00am ET, 4:00pm CEST PCR (Polymerase Chain Reaction) has gone through a massive evolution since its development in 1983. Besides it...
    AUG 27, 2019 09:00 AM PDT
    C.E. CREDITS
    AUG 27, 2019 09:00 AM PDT
    DATE: August 27, 2019 TIME: 9:00am PDT, 12:00pm EDT Immunotherapies targeting PD-1 or PD-L1 have proven remarkably effective for treating cancer in some patients, with considerabl...
    MAY 16, 2019 04:00 PM CEST
    C.E. CREDITS
    MAY 16, 2019 04:00 PM CEST
    DATE: May 16, 2019TIME: 7:00am PDT, 10:00am EDT, 4:00pm CEST The emergence of NGS is revolutionizing the microbiological sciences and transforming medicine. Deep sequencing has...
    JUL 31, 2019 09:00 AM PDT
    C.E. CREDITS
    JUL 31, 2019 09:00 AM PDT
    DATE: July 31, 2019TIME: 9:00am PT, 12:00pm ET The choroid plexus, which makes up the blood-cerebrospinal fluid barrier in the central nervous system (CNS), lines the ventricle...
    JUN 19, 2019 10:00 AM PDT
    JUN 19, 2019 10:00 AM PDT
    DATE: June 19, 2019TIME: 10:00am PDT, 1:00pm EDT As we develop new methods to create more biologically relevant models for research in understanding disease etiology and in...
    OCT 02, 2019 11:00 AM PDT
    OCT 02, 2019 11:00 AM PDT
    DATE: October 2, 2019TIME: 11:00am PDT, 2:00pm EDT Ditch the Excel spreadsheets and manage your molecular workflows entirely in your LIMS Achieve configuration of molecular workf...
    Loading Comments...
    Show Resources